Equity sell off - the real deal? Strategy update from Michael Frazis

HIMS, NU, MELI, AMD & Aussie Biotech

Anteris CEO explains why their new biomimetic heart valve can take serious market share in a $10 billion market. It's currently implanted in over 100 patients, and surgeons are delighted with the results. The market is sleeping on this one...

Mike and Ellianna discuss

#87 - Google earnings, and was that a low in semis and biotech? Mike and Ellianna discuss

Mike and Ellianna discuss the latest market moves.Sections00:00 - US Tariffs and Market Reactions06:35 - Managing Risk12:41 - Opportunities in Tech and Healthcare21:18 - Reddit23:54 - Market Dynamics and Short Selling28:54 - Clarity's Market Position and Future Prospects33:43 - Biotech Sector Valuation and Mispricing35:55 - Interest Rates and Economic Implications39:50 - Future Investment Strategies and Growth Opportunities

00:00 Welcome Back and Market Overview03:05 Navigating the Macro Environment05:59 Company Developments and Fast Track Designations09:11 Short Selling and Market Sentiment12:08 Innovations in PSMA Targeting Agents15:03 Financing Strategies and Market Positioning17:46 Clinical Trials and Sensitivity Improvements21:14 Regulatory Pathways and Market Entry24:00 Future Prospects and Market Dynamics35:30 Market Opportunities and Product Expansion35:59 Advancements in Diagnostics and Treatment39:03 Dose Optimization and Clinical Trials43:59 Patient Responses and Safety Profiles47:02 Future Directions and Phase Three Trials50:59 Navigating the Biotech Landscape52:47 Competitor Analysis and Market Positioning57:57 Innovations in Cancer Treatment

00:00 - Introduction to Radiopharmaceuticals and PSMA03:00 - Current State of PSMA in Prostate Cancer Treatment06:04 - Comparative Analysis: US vs Australia in Radiopharmaceuticals09:02 - Imaging Techniques and Their Impact on Diagnosis12:14 - The Patient Journey: From Diagnosis to Treatment14:56 - Challenges in Sensitivity and Specificity of Imaging17:57 - Post-Treatment Monitoring and Biochemical Recurrence21:09 - Innovations in Radiopharmaceuticals and Future Directions23:57 - Market Dynamics and Regulatory Challenges26:56 - Conclusion and Future of Prostate Cancer Imaging36:05 - Advancements in Targeted Therapies for Prostate Cancer41:12 - The Future of Combination Therapy42:52 - Imaging Innovations in Cancer Detection44:45 - Challenges in Treatment Approval and Reimbursement51:46 - The Role of Multiple Targets in Cancer Therapy54:40 - Exploring New Agents and Their Applications01:00:14 - The Need for Improved Reimbursement Pathways

Equity sell off - the real deal? Strategy update from Michael Frazis

00:0 True Customer Love and Explosive Growth02:05 - Portfolio update04:09 - Hims: A Case Study in True Customer Love and Explosive Growth07:18 - Defining True Customer Love11:33 - The Future of Hims and Market Dynamics in GLP-1sClarity's Fast-Tracked Approval and Market Response27:06 - Short Selling in CU629:59 - If you want to be valued like a US biotech company, you have to be capitalized like one32:10 - Clarity's FDA trial timeline36:33 - Updates from Nubank and MercadoLibre 40:54 - Customer Love and Explosive Growth44:45 - Identifying Explosive Growth Opportunities52:02 - Influence of Tech Leaders on Market Trends59:30 - Long-Term Perspectives on Semiconductor Growth

#82: Ellianna joins to talk DeepSeek, winners and losers, and 2024 in review